Marvel Biosciences extends private placement to Quebec investors

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), a Calgary-based pre-clinical stage biotechnology company, has expanded its private placement to include investors resident in the Province of Quebec, according to a press release statement.

The expansion builds on a private placement first announced on July 16, 2026. An amended and restated offering document dated August 19, 2026, is available in both English and French through the company's profile on the SEDAR+ website.

The securities offered are not registered under the United States Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons absent an applicable exemption from registration requirements.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., focuses on developing synthetic chemical derivatives of known, off-patent drugs. The company's current pipeline targets the A2a adenosine receptor, with potential applications in neurological conditions including depression, anxiety, Alzheimer's disease, and ADHD, as well as cancer and non-alcoholic steatohepatitis.

You May Also Be Interested In

• Nuvectis Pharma (NVCT) files $200M mixed shelf
• Noodles & Company (NDLS) files $100M mixed shelf
• Myriad Uranium completes acquisition of Rush Rare Metals